We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Interest in Commercial Applications for Proteomics Continues to Grow

By LabMedica International staff writers
Posted on 15 Oct 2014
Print article
Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies.

Proteomics is the study of the structure and function of proteins. This includes the study of which proteins are expressed, when and where they are expressed, and of interactions with proteins and other types of molecules. Many drug targets are proteins, and proteomics is an important tool for identification and characterization of novel drug targets. Furthermore, proteomics is an important tool for the identification of novel biomarkers and biomarker panels for diagnosis of diseases.

Among the significant business connections cited in the recent report “Proteomics Markets for Research and IVD Applications” published by Kalorama Information (New York, NY, USA) were:

Thermo Fisher Scientific (Milford, MA, USA) and Nuclea Biotechnologies (Pittsfield, MA, USA) will develop multiplexed mass spectrometry-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations.

BG Medicine (Waltham, MA, USA) and Kindstar Diagnostics (China) announced an agreement under which Kindstar will offer galectin-3 testing services in China.

Biocartis (Mechelen, Belgium) and Invetech (Melbourne (Australia) announced a collaboration agreement to support development and manufacture of Evalution, Biocartis’ advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers. Invetech provides instrument development, custom automation, and contract manufacturing.

“There is a lot of interest in identification and validation of novel biomarkers that may represent potential drug targets or may lead to novel diagnostic tests,” said Bruce Carlson, publisher of Kalorama Information. “Researchers are looking to proteomics for these discoveries.”

Related Links:

Kalorama Information


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.